A platform launch for a single-cell transcriptomics company readying its Series B. We built the brand, the launch site, and a 90-second film that played at JPM before Parse had even booked a suite.
Parse.Nova had the data — a single-cell transcriptomics platform that clustered cell types with a precision that made the incumbents' tools look like rounding errors. What they didn't have was a surface. Their old site looked like a 2019 wet-lab blog. Their deck opened with a stock photo of a pipette.
We had 14 weeks before the JPM Healthcare Conference. Success meant a site, a launch film, and a brand system that could carry them through the crossover round and into IPO conversations in 2027.
We ran three production tracks in parallel. A brand track established the type system (custom grotesk display, mono for data, editorial serif for moments of intimacy), the color (deep ink + a single lime-yellow hit), and a logotype that fragments under rotation — a literal centrifuge of the wordmark.
The web track launched at parse.nova with a full-bleed reel hero, a scroll-through platform tour rendered in WebGL, and an IR section that doubles as a recruiting surface.
The film track produced a 90-second hero and six 15-second cutdowns for social, built around a single visual conceit: every cell is a letter, every tissue is a paragraph, every organism is a novel.
The film ran at JPM. The site launched five days before. Inbound from VCs tripled in the first two weeks. By the end of Q3, Parse had closed an $86M crossover at a 2.4× step-up from the Series A — and, according to the CEO, "half the partners we met with opened the meeting by quoting lines from the site."
We're still retained on a quarterly basis for ongoing product marketing, conference creative, and IR content as they head toward filing.